ライフサイエンスコーパス: adrenergic

1 Finally, we study how local adrenergic activation can substitute for the Reissner fi

2 rated from adipose tissue lipolysis and beta-adrenergic activation of brown adipose tissue (BAT).

3 Acute mental stress elicited an alpha-adrenergic activation pattern and cardiac stress hyperre

4 tional profile suggestive of increased basal adrenergic activation.

5 in HR during SNS and was exacerbated by beta-adrenergic activation.

6 D2, PHOX2B, TBX2 and ISL1-all members of the adrenergic (ADRN) neuroblastoma core regulatory circuitr

7 inson disease (PD) associated with the beta2 adrenergic agonist (beta2-agonist) salbutamol.

8 cold exposure and injection with the beta(3) adrenergic agonist CL 316, 243(CL)].

9 loss of consciousness (LOC) with the alpha2-adrenergic agonist dexmedetomidine and return of conscio

10 reatment with a single high dose of the beta-adrenergic agonist isoproterenol.

11 Encephalopathy severity and adrenergic agonist medication exposure were the primary

12 a to alpha(1C) I-II loop and eliminated beta-adrenergic agonist stimulation of Ca(V)1.2 current.

13 ertension induced by phenylephrine, an alpha-adrenergic agonist, did not cause AAA or rupture in Apln

14 d to study the effect of salbutamol, a beta2-adrenergic agonist, on synaptic structure and function.

15 used as models to validate our methods: beta-adrenergic agonistic activity on cAMP generation (dedica

16 , we found that sedation induced with alpha2-adrenergic agonists (e.g., dexmedetomidine) and sleep ho

17 rolonged fasting, and administration of beta-adrenergic agonists (norepinephrine and CL-316243).

18 tes to examine the physiological response to adrenergic agonists and beta-blocker treatment.

19 beta2-adrenergic agonists are an effective treatment for DOK7-

20 The alpha2-adrenergic agonists are unique.

21 The precise mechanism of action of beta2-adrenergic agonists at the NMJ is not fully understood.

22 ong-term follow-up for the addition of beta2-adrenergic agonists for a cohort of patients with acetyl

23 In this study, we investigated whether beta2-adrenergic agonists improve both neurotransmission and s

24 hibition could potentiate the effect of beta-adrenergic agonists in the treatment of obesity and its

25 These findings suggest that beta-adrenergic agonists lead to functional benefit in the Co

26 t that isoproterenol (ISO) and related beta2-adrenergic agonists reacidify lysosomes in PSEN1 Knock o

27 The beta-adrenergic agonists salbutamol and ephedrine have proven

28 Here we identify the mechanism by which beta-adrenergic agonists stimulate voltage-gated calcium chan

29 d not attenuate stimulatory response to beta-adrenergic agonists when reconstituted heterologously wi

30 ere stimulated with cholinergic and alpha(1)-adrenergic agonists, vasoactive intestinal peptide (VIP)

31 to deficient vATPase and its rescue by beta2-adrenergic agonists.

32 ips, calcium handling, and responses to beta-adrenergic agonists.

33 nhibition of Ca(2+) channel activity by beta-adrenergic agonists/PKA also requires this rigid linker

34 ryptamine (serotonin) 5-HT(1b) receptors and adrenergic alpha(2a) receptors.

35 Targets include the beta-adrenergic and adenosine receptors.

36 beta(2)-adrenergic and M(2)-muscarinic receptor mRNA and beta(2)

37 with a worse outcome as compared with other adrenergic and nonadrenergic vasoactive drugs.

38 Adrenergic receptors are mediators of adrenergic and noradrenergic modulation throughout the b

39 Awakening by the alpha2-adrenergic antagonist completely eliminated this interme

40 e fight-or-flight response is caused by beta-adrenergic augmentation of Ca(V)1.2 voltage-gated calciu

41 y beta-adrenergic pathway agonists, and thus adrenergic augmentation of contractility is markedly imp

42 -adrenergic receptors (alpha(2a)ARs) in both adrenergic (auto-alpha(2a)ARs) and non-adrenergic neuron

43 ID was increased in the non-EE Andeans after adrenergic blockade (P=0.012), but this effect was not o

44 Adrenergic blockade fully restored EDD in lowlanders at

45 ropranolol is an approved non-selective beta-adrenergic blocker that is first line therapy for infant

46 oto- and bio-transformations, including beta-adrenergic blockers, antivirals, antibiotics, and pestic

47 ipheral chemoreceptors, which also activates adrenergic C1 cells.

48 e developed a context-specific model of beta-adrenergic cardiac hypertrophy.

49 g insights into new-found crosstalks in beta-adrenergic cardiac hypertrophy.

50 ta-hydroxylase (DBH; marker of noradrenergic/adrenergic cells) did not affect body growth.

51 including transcription factors forming the adrenergic core regulatory circuitry that controls the m

52 KCNJ2 mutation R67Q(+/-) causes adrenergic-dependent loss of I(K1) during terminal repol

53 ouse models of oral cancer, we identified an adrenergic differentiation signature.

54 els under conditions accompanied by enhanced adrenergic drive plays a central role in disease-related

55 repolarization under conditions of enhanced adrenergic drive.

56 delta-opioid and kappa-opioids and alpha (2)-adrenergic drugs.

57 ne growth restriction (IUGR) have shown that adrenergic dysregulation was associated with low insulin

58 ranscription factor, independent of any anti-adrenergic effect.

59 ff-target interactions at serotoninergic and adrenergic G-protein-coupled receptors (GPCRs), common o

60 hancers, driving a transcriptionally encoded adrenergic gene expression program that was selectively

61 ria of a functional thermostabilized beta(1)-adrenergic GPCR (beta(1)AR) by solution NMR.

62 rized involve engagement with targets in the adrenergic, hypothalamic-pituitary-adrenal axis, and neu

63 hymal neuroblastoma was sufficient to induce adrenergic identity and sensitize cells to CYC065.

64 milieu and facilitate their maturation into adrenergic infiltrating nerves.

65 the number of spontaneous contractions upon adrenergic isoproterenol stimulation and nearly abolishe

66 on of stress response genes by activating an adrenergic-like receptor in the intestine.

67 sive and appetitive learning, and the alpha1 adrenergic-like receptor OAMB in appetitive learning.

68 rt that octopamine activity through the beta-adrenergic-like receptor Octbeta1R drives aversive and a

69 the absence of NAMPT in WAT markedly reduced adrenergic-mediated lipolytic activity, likely through i

70 lutionarily conserved mechanism that confers adrenergic modulation upon voltage-gated calcium channel

71 PAR3 signaling pathway and is independent of adrenergic muscle contractions.

72 Recent work indicates that newly formed adrenergic nerve fibres promote tumour growth, but the o

73 Intratumoral adrenergic nerves release noradrenaline to stimulate ang

74 ot by chemical sympathectomy of pre-existing adrenergic nerves.

75 en together, we propose a novel role for the adrenergic nervous system in regulating circulating lymp

76 ribe one such signal that is provided by the adrenergic nervous system, and demonstrate that cell-int

77 ulation of the antiviral NK cell response by adrenergic neuroendocrine signals.

78 both adrenergic (auto-alpha(2a)ARs) and non-adrenergic neurons (hetero-alpha(2a)ARs) for the first t

79 s Ca2+ channels cannot be stimulated by beta-adrenergic pathway agonists, and thus adrenergic augment

80 s revealed significant co-expression of beta-adrenergic pathway genes PKA regulatory subunit type I,

81 NCLX deletion transforms the adrenergic pathway responsible for thermogenesis activat

82 sociated neurons are reprogrammed towards an adrenergic phenotype that can stimulate tumour progressi

83 Tumors also rewire established nerves to adrenergic phenotypes via exosome-induced neural reprogr

84 thrombotics, antibiotics, opioid analgesics, adrenergics, proton-pump inhibitors, nitroglycerin, diaz

85 We investigated adrenergic receptor (ADR) beta2 desensitization by admin

86 in glucose homeostasis with associated beta adrenergic receptor (ADRbeta) desensitization.

87 ial growth factor receptor, or the alpha (1)-adrenergic receptor (alpha (1)-AR).

88 The alpha(2a)-adrenergic receptor (alpha(2a)-AR) agonist guanfacine ha

89 ) mediate the post-Golgi export of alpha(2B)-adrenergic receptor (alpha(2B)-AR), a prototypic GPCR, a

90 were prevented by incubation with the alpha1 adrenergic receptor (alpha1-AR) antagonist prazosin.

91 in vascular smooth muscle coordinates alpha1-adrenergic receptor (alpha1-AR) vasoconstriction and blo

92 LOBP has been attributed to beta(2)-adrenergic receptor (B2AR) downregulation, a process req

93 The beta(1)-adrenergic receptor (beta(1)-AR) is a major regulator of

94 lating a neuroprotective program via beta(2)-adrenergic receptor (beta(2)-AR) signaling and mediated

95 lphas and Galphaq C termini with the beta(2)-adrenergic receptor (beta(2)-AR), targeted at the G-prot

96 Clenbuterol, a beta(2)-adrenergic receptor (beta(2)AR) agonist enhances skeleta

97 ingle amino acid substitutions to the beta-2 adrenergic receptor (beta(2)AR) at four concentrations o

98 The beta(2) adrenergic receptor (beta(2)AR) is an archetypal G prote

99 ics studies on ligand binding to the beta(2)-adrenergic receptor (beta(2)AR) suggested that ligands p

100 iophysical properties of a GPCR, the beta(2)-adrenergic receptor (beta(2)AR), in high-density lipopro

101 imary Gi/o-coupling receptor and the beta(2)-adrenergic receptor (beta(2)AR, which primarily couples

102 n receptor (GCGR; family B) with the beta(2) adrenergic receptor (beta(2)AR; family A).

103 beta-Adrenergic receptor (beta-AR) agonists are the most comm

104 timuli and the subsequent activation of beta-adrenergic receptor (beta-AR) potently stimulate adipose

105 rapies to improve heart function target beta-adrenergic receptor (beta-AR) signaling and Ca(2+) handl

106 beta-Adrenergic receptor (beta-AR) signaling is a pathway con

107 We found that administration of the beta1-adrenergic receptor (beta1AR) blocker atenolol during CS

108 We demonstrate here a role for the beta2-adrenergic receptor (beta2-AR), which binds the stress m

109 beta2-adrenergic receptor (beta2AR) agonists are a mainstay of

110 sed an active-state structure of the beta(2)-adrenergic receptor (beta2R) to build beta2R-WT and beta

111 BACKGROUNDMirabegron is a beta3-adrenergic receptor (beta3-AR) agonist approved only for

112 A robust change in abundance of the beta3-adrenergic receptor (beta3-AR) is observed in brown/beig

113 r ROS or antioxidant treatment affects beta3-adrenergic receptor (beta3-AR) stimulation-induced adipo

114 anisms underlying synaptic responses to beta-adrenergic receptor (betaAR) activation remain poorly un

115 Activation of the beta-adrenergic receptor (betaAR)/cAMP/protein kinase A (PKA)

116 ipocyte lipolysis by fasting (24 h) or beta3-adrenergic receptor activation by CL316, 243 (CL) increa

117 Prolonged adrenergic receptor activation, however, has deleterious

118 e encoding lactate transporter MCT2 and beta-adrenergic receptor ADRB2, are strongly (~20-fold) up-re

119 P) with a regularly used long-acting beta(2)-adrenergic receptor agonist (LABA) is well documented.

120 o cold temperatures or treated with the beta-adrenergic receptor agonist CL316,243 and that its expre

121 we report a role of Tregs in enhancing beta3-adrenergic receptor agonist CL316243 (CL)-stimulated the

122 an also benefit from the addition of a beta2-adrenergic receptor agonist to their medication.

123 ial agonists (eg, buprenorphine), and alpha2-adrenergic receptor agonists (eg, clonidine and lofexidi

124 nic fat cells that can be activated by beta3-adrenergic receptor agonists.

125 ailure work by targeting GPCRs, such as beta-adrenergic receptor and angiotensin II receptor antagoni

126 We probed the effects of the beta-adrenergic receptor antagonist propranolol (40 mg) using

127 Propranolol is a nonselective beta-adrenergic receptor antagonist that is efficacious in re

128 s increased by treatment with IL-4 or a beta-adrenergic receptor antagonist.

129 nonmotor symptoms of PD that were rescued by adrenergic receptor antagonists.

130 a oligomers induce acute wakefulness through Adrenergic receptor b2 (Adrb2) and Progesterone membrane

131 lkaloids were evaluated for their opioid and adrenergic receptor binding and functional effects, in v

132 dilation) before and after local alpha+beta adrenergic receptor blockade (phentolamine and propranol

133 to characterize the appropriate use of beta-adrenergic receptor blockers (beta-blockers) in the cont

134 lies on pharmacological therapy, mostly beta-adrenergic receptor blockers (specifically, propranolol

135 in the IC and provide the first evidence for adrenergic receptor expression and co-expression in the

136 These data suggest a coordinated pattern of adrenergic receptor expression in the IC and provide the

137 Using the beta-adrenergic receptor family as a model, we demonstrate th

138 vation is abolished by deletion of alpha(1A)-adrenergic receptor from astroglia, indicating that nore

139 We have identified a mutation in the beta(1)-adrenergic receptor gene in humans who require fewer hou

140 crystal structure of the prototypic beta(2)-adrenergic receptor in complex with an orthosteric agoni

141 adrenergic stress or signaling through beta-adrenergic receptor is reduced.

142 tagamma sink betaARK1-ct (C terminus of beta-adrenergic receptor kinase-1) was coexpressed with TRPM3

143 phosphorylating the LTB4 receptor using beta adrenergic receptor kinase.

144 so reversed by an inhibitory peptide to beta-adrenergic receptor kinase.

145 s previously not been described for beta (2)-adrenergic receptor ligands, and one of them shows an in

146 evant responses was corroborated using beta2-adrenergic receptor ligands.

147 ambs, IUGR lambs and IUGR lambs treated with adrenergic receptor modifiers: clenbuterol atenolol and

148 n this process and the importance of beta(2)-adrenergic receptor signaling.

149 angiotensin aldosterone signaling and beta-2 adrenergic receptor signaling.

150 ronic cold adaptation in the absence of beta-adrenergic receptor signalling.

151 tics(3,4), cell ablation and knockout of the adrenergic receptor specifically in melanocyte stem cell

152 Three predicted mutations in beta(2)-adrenergic receptor stabilize binding of noncognate Galp

153 ng method to study the effects of acute beta-adrenergic receptor stimulation (through isoproterenol (

154 myocardial function was unchanged, but beta-adrenergic receptor stimulation of cardiac inotropy, cAM

155 is a key negative regulator of cardiac beta-adrenergic receptor stimulation.

156 certain the modulatory potential of multiple adrenergic receptor subtypes in a single IC cell, we mea

157 transmembrane helices 6 and 7 of the beta(1)-adrenergic receptor to agonist stimulation and coupling

158 y, of a single active human chimeric beta(2)-adrenergic receptor with the C-terminal tail of the argi

159 cardioprotective effects of an alpha-1A-AR (adrenergic receptor) agonist.

160 d combined influences of beta(1)-AR (beta(1)-adrenergic receptor) stimulation and peripheral O(2) sat

161 up-regulated Adrb2 (which encodes the beta2-adrenergic receptor), a process dependent on IL-12 and S

162 unreported dissimilar ligands of the beta(2)-adrenergic receptor, and the optimization of one series

163 We focused on the beta (2)-adrenergic receptor, as it is currently the receptor wit

164 s in a challenging way, we chose the beta(2)-adrenergic receptor, for which a large number of ligands

165 s (GPCRs), such as rhodopsin and the beta(2) adrenergic receptor, have provided a picture of how stru

166 have been associated with IgGs against beta2-adrenergic receptor, muscarinic-2 receptors, AChR-nicoti

167 tu hybridization to detect the expression of adrenergic receptor-encoding mRNA in the inferior collic

168 ortions of cells in the IC that expressed no adrenergic receptor-encoding mRNA, alpha1 and alpha2A ad

169 c receptor-encoding mRNA, alpha1 and alpha2A adrenergic receptor-encoding mRNA, and alpha1, alpha2A,

170 ectrical stimulation (PNES) resulted in beta-adrenergic receptor-mediated-accumulation of B and T cel

171 alently conjugated TIL region from the beta1-adrenergic receptor.

172 f the compound for beta(2)- over the beta(1)-adrenergic receptor.

173 rhomboid protease GlpG and the human beta(2)-adrenergic receptor.

174 M egress of HSPCs and leukocytes via beta(3)-adrenergic receptor.

175 ple conformational states of a phospho-beta2 adrenergic receptor/beta-arrestin-1(beta-arr1) membrane

176 ling dogma holds that activation of the beta-adrenergic receptor/cAMP/protein kinase A signalling pat

177 M noradrenergic innervation promotes beta(2)-adrenergic-receptor(AR)-interleukin-6-dependent megakary

178 s produced from brown adipocytes in a beta-3-adrenergic-receptor-dependent fashion.

179 ipogenesis and adult deletion enhances beta3-adrenergic-receptor-induced beige adipocyte formation.

180 We previously reported alpha(1D)-adrenergic receptors (alpha(1D)-ARs) - key regulators of

181 alpha(1D)-adrenergic receptors (alpha(1D)-ARs) - key regulators of

182 tagamma specificity of presynaptic alpha(2a)-adrenergic receptors (alpha(2a)ARs) in both adrenergic (

183 in dorsal raphe neurons is driven via alpha1-adrenergic receptors (alpha1-A(R)) activation.

184 ther organ thermogenesis occurs through beta-adrenergic receptors (AR), and considerable effort over

185 We find that activation of alpha(2A)-adrenergic receptors (ARs) by the agonist guanfacine red

186 regulatory loops via activation of distinct adrenergic receptors (ARs), and their ES-evoked activati

187 deubiquitinases regulate myocardial beta(1)-adrenergic receptors (beta(1)ARs) is unknown.

188 Agonists of beta(2) adrenergic receptors (beta(2)AR) and glucocorticoid rece

189 Adipose tissue contains beta3-adrenergic receptors (beta3-ARs), and this study was int

190 o enhanced signaling through adipocyte beta3-adrenergic receptors (beta3-ARs), indicating that barr2

191 It is unclear whether cAMP generated by beta-adrenergic receptors (betaARs) is required for PF-PC LTP

192 d through the neuromodulatory action of beta-adrenergic receptors (betaARs).

193 and intra-BLA or systemic antagonism of beta-adrenergic receptors abolished both long-term pain-induc

194 Here we investigate the effect of chronic adrenergic receptors activation on excitation-contractio

195 e unconsciousness selectively through alpha2-adrenergic receptors and related circuits.

196 num ratio directly measuring the function of adrenergic receptors and sympathetic integrity (from the

197 Adrenergic receptors are mediators of adrenergic and nor

198 ynaptic plasticity, while activation of beta-adrenergic receptors elevates cAMP levels and modulates

199 al regulator of signaling downstream of beta-adrenergic receptors in cardiomyocytes.

200 have provided evidence for the expression of adrenergic receptors in the midbrain auditory nucleus, t

201 aarr1 in complex with M2 muscarinic or beta2-adrenergic receptors reconstituted in lipid nanodiscs ac

202 Stress hormone signaling through beta-adrenergic receptors regulates macrophage mechanotype an

203 acological ablation of sympathetic nerves or adrenergic receptors to assess their relevance for rhyth

204 Activation of glial alpha1-adrenergic receptors triggers rapid astrocytic Ca(2+) el

205 higher affinity at opioid receptors than at adrenergic receptors while the vice versa was observed f

206 er studies using mice lacking beta2AR (beta2 adrenergic receptors) indicate that beta2AR in the bone

207 eas gene expression of ADRB1 (encoding beta1-adrenergic receptors) was decreased at ZT14 versus ZT4 i

208 the host via interaction with multiple ARs (adrenergic receptors)-a class of key receptors that regu

209 y denervation or pharmacological blockade of adrenergic receptors, but not by chemical sympathectomy

210 nse hormone norepinephrine to stimulate beta-adrenergic receptors, cAMP production, and protein kinas

211 mediated by ET(A), thromboxane, and alpha(2)-adrenergic receptors, respectively, and were insensitive

212 ts with adenosine A1, GABA(B), and alpha(2A)-adrenergic receptors, through a mechanism involving both

213 silon in response to the stimulation of beta-adrenergic receptors, translocating the complex to the p

214 c function via activation of post-junctional adrenergic receptors.

215 obiota-dependent metabolite that signals via adrenergic receptors.

216 ptors, including alpha2A, alpha2B, and beta2-adrenergic receptors.

217 such as GABA(B), adenosine A1- and alpha(2A)-adrenergic receptors.

218 I(Na), I(Kur), I(CaL), I(CaT), I(f) and beta-adrenergic receptors.

219 at AITC inhalation in SH rats evokes de novo adrenergic reflexes following vagal afferent activation.

220 ng an approach to specifically modulate beta-adrenergic regulation of cardiac contractility.

221 ate that beta subunits are required for beta-adrenergic regulation of CaV1.2 channels and positive in

222 vel pH modulation of lysosomes through beta2-adrenergic regulation of ClC-7, which can potentially be

223 ith structural remodeling and a blunted beta-adrenergic response.

224 In conclusion, altered myocyte adrenergic responses in the peri-infarct but not the rem

225 highlight the importance of altered myocyte adrenergic responses in the peri-infarct region as sourc

226 stimulated cardiac contractile function and adrenergic responsiveness by enhancing phospholamban pho

227 diac electrophysiology, Ca(2+) handling, and adrenergic responsiveness, which is disrupted with age.

228 These differences in EC coupling and beta-adrenergic sensitivity may help explain why therapies th

229 y, further aggravated by a reduction in beta-adrenergic sensitivity.

230 TFs related to inflammation (NF-kB) and beta-adrenergic signaling (CREB) and by decreased activity of

231 Drug discovery efforts targeting beta-adrenergic signaling have not been fruitful after decade

232 nic hypoxia reduces EDD via heightened alpha-adrenergic signaling in lowlanders and in Andeans with E

233 d to understand the effect of disruptions of adrenergic signaling in neurodevelopment and neuropathol

234 system, and demonstrate that cell-intrinsic adrenergic signaling is required for optimal adaptive NK

235 ein kinase A (PKA), a known node in the beta-adrenergic signaling pathway.

236 adipocytes activated by the canonical beta3-adrenergic signaling pathway.

237 Adrenergic signaling profoundly modulates animal behavio

238 Adrenergic signaling triggered by chronic stress partici

239 As a result, NK cell-intrinsic adrenergic signaling was required for protection against

240 sfunction, nutrient metabolism, cardiac beta-adrenergic signaling, action potential generation, and c

241 investigate the function of Ces3 in the beta-adrenergic signaling-activated adipocytes, we applied WW

242 , and by pharmacological stimulation of beta-adrenergic signaling.

243 by GABPalpha emerging in the absence of beta-adrenergic signaling.

244 Finally, we discuss the effect of SNS adrenergic signalling in immune cells and conclude with

245 and improved understanding of the effect of adrenergic signalling on the neuromuscular junction is e

246 tion is due to a potentiating effect on beta-adrenergic signalling, which leads to increased catechol

247 e A-an essential downstream mediator of beta-adrenergic signalling-suggesting that non-channel factor

248 stead, disease tolerance is dependent on the adrenergic state of thermogenic adipocytes, which indire

249 balance under excess glucose, rescuing beta-adrenergic-stimulated cardiac excitation-contraction cou

250 The exogenous addition of 14-3-3 to beta-adrenergic-stimulated cardiomyocytes led to prolonged SE

251 ve regional super-sensitivity to circulating adrenergic stimulation (ISO), while having blunted respo

252 Beta-adrenergic stimulation (isoproterenol, 100 nmol L(-1) )

253 t variability of repolarization (BVR) during adrenergic stimulation (isoproterenol, ISO).

254 t protein kinase II (CaMKII) at Thr(17) beta-Adrenergic stimulation and PKA-dependent phosphorylation

255 Under high glucose and beta-adrenergic stimulation conditions, palmitate can, at lea

256 intact hearts was performed before and after adrenergic stimulation in wild-type (WT) littermate cont

257 We found that beta-adrenergic stimulation led to rapidly increased Galphas

258 beta-Adrenergic stimulation of adipose tissue increases mitoc

259 Here, we show that adrenergic stimulation of BAT activates a PKA-dependent

260 During beta-adrenergic stimulation of brown adipose tissue (BAT), p3

261 Here, we investigated whether beta-adrenergic stimulation of cardiomyocytes led to stimulus

262 beta-Adrenergic stimulation of HFpEF myocytes with isoprenali

263 beta-Adrenergic stimulation of isolated adult cardiomyocytes

264 We show that Ca(2+) overload induced by adrenergic stimulation of NCLX-null BAT, triggers the mi

265 Adrenergic stimulation of NCLX-null brown adipocytes (BA

266 hway through which BA evade apoptosis during adrenergic stimulation of uncoupling.

267 -sequestering peptide sharply curtailed beta-adrenergic stimulation of WT Ca2+ channels, identifying

268 Ps) in ventricular cardiomyocytes under beta-adrenergic stimulation or in disease states remains unde

269 R67Q(+/-) myocytes (n=10) under adrenergic stimulation showed frequent spontaneous devel

270 c function, and heart rate responsiveness to adrenergic stimulation were limited.

271 d ventricular myocytes at baseline and after adrenergic stimulation were performed in WT and R67Q(+/-

272 n the peri-infarct and remote regions during adrenergic stimulation with isoproterenol (isoprenaline;

273 db/db mice subjected to stress given by beta-adrenergic stimulation with isoproterenol and high gluco

274 Upon cold or beta-adrenergic stimulation, Aifm2 associates with the outer

275 odulated under basal conditions, during beta-adrenergic stimulation, and in heart failure by mechanis

276 activity under basal conditions, during beta-adrenergic stimulation, and in heart failure.

277 At baseline and following adrenergic stimulation, DMD hiPSC-derived cardiomyocytes

278 We found that, following adrenergic stimulation, the BAT temperature of knockout

279 and functional responses downstream of beta-adrenergic stimulation.

280 microenvironment but is depleted during beta-adrenergic stimulation.

281 n 7 and phosphorylated perilipin-1 following adrenergic stimulation.

282 e displayed aberrant action potentials after adrenergic stimulation.

283 Doppler analysis at rest and following beta-adrenergic stimulation.

284 witch force generation, and response to beta-adrenergic stimulation.

285 VB rats and worsened when combined with beta-adrenergic stimulation.

286 d excitation-contraction coupling after beta-adrenergic stimulation.

287 doplasmic reticulum (ER) in response to beta-adrenergic stimulation.

288 ibility that cardiomyocyte responses to beta-adrenergic stimulus are also highly heterogeneous.

289 alone is highly dependent upon the degree of adrenergic stress in the tumor-bearing host.

290 nt tumors, including metastatic tumors, when adrenergic stress or signaling through beta-adrenergic r

291 These data suggest that blockade of beta2 adrenergic stress signaling could be a useful, safe, and

292 ia propensity, and is further exacerbated by adrenergic stress.

293 I) enhances I(Na,L) in response to increased adrenergic tone.

294 We show that loss of TP53 leads to adrenergic transdifferentiation of tumour-associated sen

295 mpathetic nerves underwent a dopaminergic-to-adrenergic transition during post-natal development of t

296 We found that adrenergic uptake inhibitors, specifically amitriptyline

297 l stimulus of the embryo and is regulated by adrenergic uterine smooth muscle contractions.

298 eletal muscle to attenuate sympathetic alpha-adrenergic vasoconstriction ('functional sympatholysis')

299 nalling during exercise attenuated alpha(1) -adrenergic vasoconstriction in the contracting muscle of

300 r tone, endothelium-dependent dilatation and adrenergic vasoconstriction increased at 10 days in conc